MoonLake Immunotherapeutics (MLTX) EBT (2021 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly EBT of -$69.1 million for Q1 2026, down 70.98% year-over-year from -$238.0 million in Q1 2025, and down 10.06% quarter-over-quarter from -$62.8 million in Q4 2025.
MoonLake Immunotherapeutics (MLTX) EBT (2021 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' EBT history runs 6 years deep, the most recent figure standing at -$69.1 million for Q1 2026.
- In Q1 2026, EBT fell 70.98% year-over-year to -$69.1 million; the TTM figure through Mar 2026 stood at -$258.4 million (down 75.22% YoY), while the FY2025 annual figure was -$229.7 million, down 89.9% from the prior year.
- EBT for Q1 2026 stood at -$69.1 million, down from -$62.8 million in the prior quarter.
- The five-year high for EBT was -$7.8 million in Q4 2023, with the low at -$70.6 million in Q3 2025.
- The 5-year median for EBT is -$17.4 million (2022), against an average of -$31.1 million.
- Peak annual rise in EBT reached 69.32% in 2022, while the deepest fall reached 20705.61% in 2022.
- MoonLake Immunotherapeutics' EBT stood at -$16.5 million in 2022, then surged by 52.34% to -$7.8 million in 2023, then slumped by 491.0% to -$46.4 million in 2024, then sank by 35.41% to -$62.8 million in 2025, then fell by 10.06% to -$69.1 million in 2026.
- Business Quant data shows MLTX's EBT at -$69.1 million in Q1 2026, -$62.8 million in Q4 2025, and -$70.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - | -61.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61.72 Mn |
| Mar 31, 2026 | -69.09 Mn |
| Dec 31, 2025 | -62.77 Mn |
| Sep 30, 2025 | -70.58 Mn |
| Jun 30, 2025 | -55.96 Mn |
| Mar 31, 2025 | -40.41 Mn |
| Dec 31, 2024 | -46.35 Mn |
| Sep 30, 2024 | -36.02 Mn |
| Jun 30, 2024 | -24.68 Mn |
| Mar 31, 2024 | -13.91 Mn |
| Dec 31, 2023 | -7.84 Mn |
| Sep 30, 2023 | -11.59 Mn |
| Jun 30, 2023 | -12.34 Mn |
| Mar 31, 2023 | -12.21 Mn |
| Dec 31, 2022 | -16.46 Mn |
| Sep 30, 2022 | -14.73 Mn |
| Jun 30, 2022 | -17.41 Mn |
| Mar 31, 2022 | -15.87 Mn |
| Dec 31, 2021 | -53.64 Mn |
| Sep 30, 2021 | -6.29 Mn |